Elraglusib by Actuate Therapeutics for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

Want To Work in Psychedelics? The Industry Needs More Trial Screeners. | Psychedelic Invest

Psychedelic clinical studies have become a cornerstone in the evolving landscape of mental health treatment. With conditions like depression, PTSD, and anxiety reaching alarming prevalence,

August 14, 2024

A novel approach to understanding protein compartmentalization

In physics, a system composed of two substances can be modeled in accordance with classical mixture theory, which considers the fraction corresponding to each constituent

October 14, 2024

Study shows the critical role of time cells in complex behavioral learning

A sense of time is fundamental to how we understand, recall, and interact with the world.

June 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.